Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Trump says US pharma tariffs coming in not-too-distant future
12:26pm, Monday, 14'th Apr 2025
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
03:20am, Monday, 14'th Apr 2025
AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
02:20pm, Friday, 11'th Apr 2025
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
10:30am, Friday, 11'th Apr 2025
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told
This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working.
08:28am, Friday, 11'th Apr 2025
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs
06:11pm, Thursday, 10'th Apr 2025
Swiss pharmaceutical giant Novartis (NVS) said it plans to invest $23 billion in the construction and expansion of 10 U.S. facilities, as drugmakers brace for potential tariffs from the Trump administ
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats
01:33pm, Thursday, 10'th Apr 2025
Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administ
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
04:45am, Thursday, 10'th Apr 2025
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
06:32pm, Wednesday, 09'th Apr 2025
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
03:59pm, Wednesday, 09'th Apr 2025
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin
Explainer: Prescription drugs become a target in Trump's trade war
02:27pm, Wednesday, 09'th Apr 2025
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
01:06pm, Wednesday, 09'th Apr 2025
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Novartis After Sandoz: The Business Without Generics
06:38am, Sunday, 06'th Apr 2025
Novartis has restructured to focus solely on innovative branded drugs, showing double-digit growth in revenue and profit in 2024. The company is strong in oncology, cardiology, immunology, and neurolo
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
11:50am, Thursday, 03'rd Apr 2025
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
09:14am, Thursday, 03'rd Apr 2025
Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment. The post Novartis Pops — Hammering Rival Travere Therapeutic
